Overall, this data supports that SIN3A and SIN3B expression levels in cancer patients will depend on molecular subtype; and in triple negative breast cancer, lowered expression of SIN3A and higher expression of SIN3B may be associated with more aggressive disease progression. Here, SIN3A is linked to triple-negative breast carcinoma.